360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

Treanda

Type: Product

Name: Treanda

First reported 13 hours ago - Updated 13 hours ago - 2 reports

Pfizer Inc

Pfizer Discontinues Its Inotuzumab Evaluation and 2 Other Dow Movers to Watch

Pfizer ( NYSE:PFE ): Current price $29.02Pfizer has recently suffered a pipeline setback with its discontinuing a late-stage evaluation being conducted with its oncology candidate, inotuzumab ozogamicin. The randomized, open-label, two-arm phase III study ... [Published Wall St. Cheat Sheet - 13 hours ago]

Entities: Pfizer Inc, Rituxan, Chemical

First reported May 20 2013 - Updated May 21 2013 - 2 reports

National Hockey League

Non-Hodgkin Rx Trial Halted

Pfizer discontinues phase III trial on investigation compound for non Hodgkin lymphoma(dailyRx News) A new medication that was thought to hold promise for non-Hodgkin lymphoma has been stopped. Pfizer announced it has halted its trial of the investigational ... [Published Daily Rx - May 21 2013]

Entities: rituximab, National Hockey League, Pfizer Inc, Non-Hodgkin's Lymphoma, Patient

First reported May 02 2013 - Updated May 03 2013 - 2 reports

Teva Pharmaceutical Industries Ltd

Teva Pharmaceutical's CEO Discusses Q1 2013 Results - Earnings Call Transcript

Teva Pharmaceutical Industries Ltd (TEVA) Q12013 Earnings Call May 2, 2013 8:00 AM ETOperatorWelcome to the Teva Pharmaceutical Industries Limited first quarter 2013 earnings conference call. My name is Sandra, and I will be your operator for today's ... [Published Seeking Alpha - May 02 2013]

Entities: Teva Pharmaceutical Industries Ltd, Copaxone, Modafinil, Treanda

First reported May 02 2013 - Updated May 03 2013 - 1 reports

Teva Q1 Profit Down - Quick Facts

Teva Pharmaceutical Industries Limited (TEVA: Quote) reported that its first-quarter net income attributable to the company decreased to $630 million or $0.74 per share, from $859 million or $0.97 per share in the same quarter last year.The company had ... [Published RTTNews.com - May 02 2013]

Entities: Teva Pharmaceutical Industries Ltd, Treanda, Azilect, Modafinil, Copaxone

First reported Mar 25 2013 - Updated Mar 25 2013 - 1 reports

Cephalon Inc

Whistleblower says Cephalon ignored DoJ pact to push off-label uses

Drugmakers being accused, sued and abused for pushing drugs for off-label uses is a regular thing in the industry. But the allegations in a recently released lawsuit against Cephalon suggest that company was particularly obscene about pushing off-label ... [Published PharmaGossip - Mar 25 2013]

Entities: Cephalon Inc, Whistle-Blower, Fentora, Treanda

First reported Mar 21 2013 - Updated Mar 22 2013 - 1 reports

Teva’s Cephalon Accused Of Fraud By Whisteblower

Two years ago, the US Attorney in New York opened an investigation into Cephalon, which was since bought by Teva Pharmaceuticals, over allegations of off-label marketing of its Treanda medication for treating chronic lymphocytic leukemia ( back story ... [Published Pharmalot - Mar 21 2013]

Entities: Cephalon Inc, Treanda, Teva Pharmaceutical Industries Ltd, Lawsuit, Fentora

First reported Dec 12 2012 - Updated Dec 12 2012 - 1 reports

bendamustine

New Combo Replaces CHOP for Lymphoma

(MedPage Today) -- ATLANTA - The combination chemotherapy known as CHOP, used for nonHodgkin's lymphoma, is rapidly being replaced by bendamustine (Treanda), frequently combined with rituximab (Rituxan), researchers reported. ... [Published MedPageToday.com - medical news plus CME for ph ... - Dec 12 2012]

Entities: lymphoma, Treanda, combination chemotherapy, bendamustine

Quotes

"Hematologic cancers are a complex group of diseases, with more than 70 different types of lymphomas, leukemias or myelomas that require unique treatment options" Mace Rothenberg, Pfizer's senior vice president of clinical development and medical affairs for its oncology business unit, said in a statement

Pfizer halts study of lymphoma drug unlikely to help survival [Published Reuters - May 20 2013]

"During the quarter, we were pleased by the overall performance of our specialty products and results of our OTC joint venture. Our generic operations, which are a core component of our business, performed in line with our expectations and were particularly strong in Western and Eastern Europe" President and CEO Jeremy Levin said

Teva First Quarter Results Top Estimates [Published RTTNews.com - May 02 2013]

More Content

sort by: Date \| Relevance
Pfizer Discontinues Its Inotuzumab Evaluation a... [Published Wall St. Cheat Sheet - 13 hours ago]
Pfizer Discontinues Its Inotuzumab Evaluation a... [Published Wall St. Cheat Sheet - 13 hours ago]
Non-Hodgkin Rx Trial Halted [Published Daily Rx - May 21 2013]
Pfizer halts study of lymphoma drug unlikely to... [Published Reuters - May 20 2013]
Teva Beats on Earnings, Revenues Zacks [Published Yahoo! Finance - May 06 2013]
Teva Pharmaceutical's CEO Discusses Q1 2013 Res... [Published Seeking Alpha - May 02 2013]
Teva First Quarter Results Top Estimates [Published RTTNews.com - May 02 2013]
Teva Q1 Profit Down - Quick Facts [Published RTTNews.com - May 02 2013]
Whistleblower says Cephalon ignored DoJ pact to... [Published PharmaGossip - Mar 25 2013]
Teva’s Cephalon Accused Of Fraud By Whisteblowe... [Published PharmaGossip - Mar 21 2013]
Teva’s Cephalon Accused Of Fraud By Whisteblower [Published Pharmalot - Mar 21 2013]
Lundbeck invests significantly in product devel... [Published GlobeNewswire - Dec 19 2012]
New Combo Replaces CHOP for Lymphoma [Published MedPageToday.com - medical news plus CME for ph ... - Dec 12 2012]

Blogs

sort by: Date \| Relevance
Pfizer Discontinues Its Inotuzumab Evaluation a... [Published Wall St. Cheat Sheet - 13 hours ago] Pfizer ( NYSE:PFE ): Current price $29.02Pfizer has recently suffered a pipeline setback with its discontinuing a late-stage evaluation being conducted with its oncology candidate, inotuzumab ozogamicin. The randomized, open-label, two-arm phase III study ...
Pfizer Discontinues Its Inotuzumab Evaluation a... [Published Wall St. Cheat Sheet - 13 hours ago] Pfizer ( NYSE:PFE ): Current price $29.02 Pfizer has recently suffered a pipeline setback with its discontinuing a late-stage evaluation being conducted with its oncology candidate, inotuzumab ozogamicin. The randomized, open-label, two-arm phase ...
Whistleblower says Cephalon ignored DoJ pact to... [Published PharmaGossip - Mar 25 2013] Drugmakers being accused, sued and abused for pushing drugs for off-label uses is a regular thing in the industry. But the allegations in a recently released lawsuit against Cephalon suggest that company was particularly obscene about pushing off-label ...
Teva’s Cephalon Accused Of Fraud By Whisteblowe... [Published PharmaGossip - Mar 21 2013] Two years ago, the US Attorney in New York opened an investigation into Cephalon, which was since bought by Teva Pharmaceuticals, over allegations of off-label marketing of its Treanda medication for treating chronic lymphocytic leukemia ( back story ...
Teva’s Cephalon Accused Of Fraud By Whisteblower [Published Pharmalot - Mar 21 2013] Two years ago, the US Attorney in New York opened an investigation into Cephalon, which was since bought by Teva Pharmaceuticals, over allegations of off-label marketing of its Treanda medication for treating chronic lymphocytic leukemia ( back story ...